Results 131 to 140 of about 1,115 (145)

Givosiran

Reactions Weekly
  +4 more sources

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

Liver International, 2022
, Manisha Balwani, Paolo Ventura
exaly  

Givosiran, a novel treatment for acute hepatic porphyrias

Expert Review of Precision Medicine and Drug Development, 2021
, Manish Thapar
exaly  

Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported

Clinical Pharmacology & Therapeutics, 2022
Bins, Sander, Sardh, Eliane, Langendonk, Janneke G.   +2 more
openaire   +2 more sources

Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?

Annals of Hematology, 2021
Petro Petrides, Petrides Petro E
exaly  

Summary of opinion: Givlaari,givosiran

Case Medical Research, 2020
openaire   +1 more source

Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta‐synthase

Journal of Internal Medicine, 2021
Daphne Vassiliou, Eliane Sardh
openaire   +2 more sources

Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP)

Journal of Medical Economics, 2020

exaly  

Personalized dosage of Givosiran in acute intermittent porphyria

Medicina Clínica (English Edition)
Manuel, Garrido Montes, Roberto, Pertusa Mataix, Jose Salvador, Garcia Morillo   +2 more
openaire   +2 more sources

FDA approves givosiran for acute hepatic porphyria

Case Medical Research, 2019
openaire   +2 more sources